NASDAQ · DRUG
Healthcare · Biotechnology
$48.25
Down-$1.54 (-3.09%)
Updated Oct 7, 2026, 8:59 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · DRUG
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
DRUG closed at $48.25 after 21 trading sessions, down 27.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $49.79 | $50.00 | $47.60 | $48.25 | 107.66K |
| Oct 5, 2026 | $50.69 | $51.335 | $49.085 | $49.79 | 55.95K |
| Oct 2, 2026 | $49.61 | $51.04 | $48.75 | $50.69 | 154.9K |
| Oct 1, 2026 | $49.54 | $52.12 | $48.53 | $49.21 | 166.99K |
| Sep 30, 2026 | $50.00 | $50.956 | $49.01 | $49.82 | 79.83K |
| Sep 29, 2026 | $53.165 | $53.165 | $49.53 | $49.74 | 96.76K |
| Sep 28, 2026 | $52.69 | $52.69 | $49.553 | $51.66 | 91.88K |
| Sep 25, 2026 | $53.33 | $54.365 | $51.41 | $51.80 | 210.97K |
| Sep 24, 2026 | $57.91 | $58.30 | $52.905 | $53.51 | 129.66K |
| Sep 23, 2026 | $60.44 | $60.44 | $56.50 | $57.92 | 90.38K |
| Sep 22, 2026 | $60.36 | $62.45 | $60.15 | $60.67 | 65.27K |
| Sep 21, 2026 | $61.98 | $61.98 | $59.175 | $59.46 | 91.66K |
| Sep 18, 2026 | $61.31 | $62.11 | $60.475 | $60.98 | 142.39K |
| Sep 17, 2026 | $60.18 | $62.26 | $59.89 | $61.55 | 67.35K |
| Sep 16, 2026 | $60.22 | $61.08 | $57.58 | $59.11 | 97.45K |
| Sep 15, 2026 | $61.90 | $61.90 | $59.245 | $60.22 | 58.99K |
| Sep 14, 2026 | $63.30 | $63.895 | $62.83 | $63.38 | 42.15K |
| Sep 11, 2026 | $66.25 | $66.25 | $62.4182 | $63.18 | 129.22K |
| Sep 10, 2026 | $63.98 | $66.00 | $63.19 | $65.00 | 86.71K |
| Sep 9, 2026 | $66.54 | $67.76 | $64.7375 | $65.06 | 43.21K |
| Sep 8, 2026 | $65.07 | $67.77 | $64.30 | $66.91 | 65.21K |
The latest Smart Investors Daily articles mentioning DRUG.
Company
Market Activity
Research & News
DRUG research
Company profile and research snapshot.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Mar 4, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and raises the price target from $115 to $145.
Yahoo · Feb 25, 2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:TD Cowen 46th Annual Health Care ConferenceDATE:Wednesday, March 4, 202
Yahoo · Feb 19, 2026
Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Bright Minds Biosciences Inc. (NASDAQ:DRUG) is among the most promising stocks. TheFly reported on February 13 that Baird lowered its price target for DRUG to $126 from $142 and maintained an Outperform rating on the shares. The update […]
Yahoo · Feb 17, 2026
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for January 2026.January 2026 Operating StatisticsTrading volume of CSE listed securities totaled 2.0 billion shares;Trading value of CSE listed securities was $1.0 billion;CSE issuers completed 83 financings that raised an aggregate $446 million; andThe CSE welcomed listings from three new companies, bringing total listed securities to 737 as at..
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DRUG.
